Galectin (GALT) director Uihlein awarded options and $40k share grant

Rhea-AI Filing Summary

Galectin Therapeutics director and 10% owner Richard E. Uihlein reported equity awards from the company. On January 16, 2026, he received 60,000 stock options with an exercise price of $3.04 per share under the Galectin Therapeutics Inc. 2019 Omnibus Equity Incentive Plan. These options vest 100% on December 31, 2026.

On the same date, he was also issued 13,158 shares of common stock at $3.04 per share in lieu of a $40,000 cash retainer and meeting fees for 2026, with restrictions on these shares lapsing 25% at the end of each calendar quarter in 2026. Following these transactions, he directly held 10,332,676 common shares and 60,000 options, and indirectly 27,710 shares through the Ed Uihlein Family Foundation, where he shares voting and dispositive power but has no pecuniary interest.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Uihlein Richard E

(Last) (First) (Middle)

4960 PEACHTREE INDUSTRIAL BLVD

SUITE 240

(Street)

NORCROSS GA 30071

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
GALECTIN THERAPEUTICS INC [ GALT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/16/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/16/2026		A		13,158(3)	A	$3.04(3)	10,332,676	D
Common Stock								27,710	I	By Ed Uihlein Family Foundation(4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock option (right to buy)(1)	$3.04	01/16/2026		A		60,000		(2)	01/16/2036	Common Stock	60,000	$0	60,000	D

Explanation of Responses:

1. The stock options were issued pursuant to the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan.

2. The options vest 100% on December 31, 2026.

3. These restricted shares were issued pursuant to the Galectin Therapeutics Inc. 2019 Omnibus Equity Incentive Plan in lieu of a cash retainer and meeting fees of $40,000 for 2026. Restrictions on the shares lapse at a rate of 25% at the end of each calendar quarter in 2026.

4. The reporting person is president and director of Ed Uihlein Family Foundation, a not-for-profit corporation. The reporting person has no pecuniary interest in the shares, however, he shares voting and dispositive power over the shares and, therefore, remains the beneficial owner of the shares solely for the purposes of Section 13(d) of the Securities Exchange Act of 1934.

	Jack W. Callicutt, by power of attorney	01/21/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did Richard E. Uihlein report for GALT on January 16, 2026?

Richard E. Uihlein reported receiving 60,000 stock options with an exercise price of $3.04 per share and 13,158 restricted shares of Galectin Therapeutics Inc. (GALT) common stock on January 16, 2026.

How do the new stock options granted to Richard E. Uihlein in GALT vest?

The 60,000 stock options granted to Richard E. Uihlein under the Galectin Therapeutics Inc. 2019 Omnibus Equity Incentive Plan vest 100% on December 31, 2026 and carry an exercise price of $3.04 per share.

Why did Galectin Therapeutics (GALT) issue 13,158 restricted shares to Richard E. Uihlein?

The 13,158 restricted shares were issued under the 2019 Omnibus Equity Incentive Plan in lieu of a cash retainer and meeting fees of $40,000 for 2026. Restrictions on these shares lapse 25% at the end of each calendar quarter in 2026.

How many Galectin Therapeutics shares does Richard E. Uihlein own directly and indirectly after these transactions?

After the reported transactions, Richard E. Uihlein directly owned 10,332,676 shares of Galectin Therapeutics common stock and 60,000 stock options. Indirectly, 27,710 shares were held by the Ed Uihlein Family Foundation, where he shares voting and dispositive power but has no pecuniary interest.

What is Richard E. Uihlein’s relationship to the Ed Uihlein Family Foundation in the GALT Form 4?

The Form 4 notes that Richard E. Uihlein is president and director of the Ed Uihlein Family Foundation, a not-for-profit corporation. He has no pecuniary interest in the 27,710 shares held by the foundation but shares voting and dispositive power, so he is treated as the beneficial owner solely for Section 13(d) purposes.